Dr Barbara Krebs-Pohl is a highly regarded business development executive with an outstanding track record of accomplishment of revenues and forging successful alliances with pharma and
biotechnology companies worldwide.
Since joining MorphoSys in 1998, Dr Krebs-Pohl has successfully led RandD teams, international alliances and negotiation teams spanning a broad variety of deal structures. She has been
instrumental in program search and evaluation, portfolio strategy and a multitude of transactions, including the in-licensing of tafasitamab from Xencor, the long-term HuCAL alliance with Novartis
and the co-development and co-commercialization partnership with Incyte. She is also the winner of the AstraZeneca Business Development Executive of the Year 2013 Award.
Prior to joining MorphoSys, Dr Krebs-Pohl earned the opportunity to work with Nobel Prize winner Sir Greg Winter at MRC/LMB Cambridge, UK. She holds a PhD from the University of Mainz in
Immunology, theoretical Physics and Biochemistry. She is a Master of Science (MSc) Chemistry from the University of Cologne and further trained at the RWTH Aachen University with focus on
Medical Biology and Bacteriology.